The company has acquired proven pellet technologies that enables controlled release of APIs
Metrics Inc of Greenville, North Carolina, US, now offers proprietary pellet technologies enabling controlled release of active pharmaceutical ingredients (API).
The company’s advanced drug delivery technology supports the therapeutic effectiveness of API by tailoring drug release to the specific application and desired end point.
For a patient, the potential benefits of this technology are fewer doses and fewer side effects, notably gastrointestinal symptoms such as nausea – thereby increasing patient compliance.
Metrics’ ability to offer these technologies results from the company’s recent acquisition by Mayne Pharma Group. This company has successfully applied pellet technology to a number of proprietary pharmaceuticals with modified release profiles, including Eryc (delayed release erythromycin), Doryx (delayed release doxycycline), Kadian (extended release morphine), Astrix (delayed release low-dose aspirin) and pulsed release diltiazem. The combined sales of these proprietary drugs exceed US$500 m annually.
'The pharmaceutical science is all about making drugs as effective and tolerable as possible so that patients can experience both better health and a better quality of life when taking necessary medications,' said Dr Brad Gold, vice president of pharmaceutical development at Metrics. 'It’s exciting to offer pellet formulation to our clients – and to the patients they seek to help.'
Metrics Inc is a global pharmaceutical development and manufacturing organisation for solid oral dosage forms.